# China NMPA Drug Inspection - Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd. - Pudilan Anti-inflammatory Tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/client-yunnan-longfa-pharmaceutical-co-ltd-contractor-yunnan-longrun-pharmaceutical-co-ltd/0209b8de-3d0a-485f-8eb4-21ac435e8523/
Source feed: China

> China NMPA drug inspection for Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd. published June 01, 2020. Drug: Pudilan Anti-inflammatory Tablets. On June 1, 2020, the Guangxi Medical Products Administration, under the National Medical Products Administration (NMPA),

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement of the Results of the Second Guangxi Drug Quality Spot Check in 2020
- Company Name: Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd.
- Publication Date: 2020-06-01
- Drug Name: Pudilan Anti-inflammatory Tablets
- Inspection Finding: Compliant
- Summary: On June 1, 2020, the Guangxi Medical Products Administration, under the National Medical Products Administration (NMPA), published the results of its second drug quality sampling inspection for the year. This regulatory oversight was conducted to ensure public medication safety and involved testing various drug production, distribution, and healthcare units throughout the Guangxi region. Major companies included in the inspection were Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd., Yunnan Baiyao Group, Yangtze River Pharmaceutical Group, and Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd.

The inspection evaluated a diverse range of products, including Acyclovir tablets, Lanqin oral liquids, and various traditional Chinese medicine granules like Xiaochaihu and Banlangen. Testing focused on critical quality parameters such as weight variation, dissolution rates, microbial limits, pH values, and the identification of active ingredients. The results of the 71 samples detailed in the attachments—covering both the production and circulation stages—showed that all tested batches were fully compliant with established quality regulations. 

The inspections were carried out under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition) and other National Drug Standards. Because the sampled batches met all safety and efficacy requirements, no violations were reported and no punitive actions were required. This announcement serves as a formal public record of the region's adherence to pharmaceutical quality standards as part of the NMPA's routine annual sampling and daily supervision program.

Company: https://www.globalkeysolutions.net/companies/client-yunnan-longfa-pharmaceutical-co-ltd-contractor-yunnan-longrun-pharmaceutical-co-ltd/4e56f2e5-58fe-4d11-80c0-e5c60482eb6f/